Meeting
2023 ASCO Annual Meeting
Primary efficacy analyses of NeoRHEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer.
Authors
Elisa Agostinetto
Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium
Elisa Agostinetto , Andreas Papagiannis , Frederic Cailleux , Mariana Brandão , Alexandra Stanciu , Denis Larsimont , Isabelle Veys , Marianne Paesmans , Tatiana Besse-Hammer , Ahmad Awada , Martine J. Piccart-Gebhart , Christos Sotiriou , Lieveke Ameye , Patrick Neven , Francois P. Duhoux , Peter Vuylsteke , Michail Ignatiadis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT03065621
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 522)
DOI
10.1200/JCO.2023.41.16_suppl.522
Abstract #
522
Poster Bd #
352
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Biomarker analysis of PALLET: A neoadjuvant trial of letrozole (L) ± palbociclib (P).
First Author: Vera Martins
Poster
2022 ASCO Annual Meeting
ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
First Author: Erika P. Hamilton
Poster
2021 ASCO Annual Meeting
Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
First Author: Erika P. Hamilton
Poster
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
First Author: Kelvin K H Bao